8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Retinoblastoma is a non-hereditary as well as an inherited pediatric tumor of the developing retina resulting from the inactivation of both copies of the RB1 tumor suppressor gene. Familial retinoblastoma is a highly penetrant genetic disease that usually develops by carrying germline mutations that inactivate one allele of the RB1 gene, leading to multiple retinoblastomas. However, large and complete germline RB1 deletions are associated with low or no tumor risk for reasons that remain unknown. In this study, we define a minimal genomic region associated with this low penetrance. This region encompasses few genes including MED4 a subunit of the mediator complex. We further show that retinoblastoma RB1 -/- cells cannot survive in the absence of MED4, both in vitro and in orthotopic xenograft models in vivo, therefore identifying MED4 as a survival gene in retinoblastoma. We propose that the contiguous loss of the adjacent retinoblastoma gene, MED4, explains the low penetrance in patients with large deletions that include both RB1 and MED4. Our findings also point to another synthetic lethal target in tumors with inactivated RB1 and highlight the importance of collateral damage in carcinogenesis.

          Related collections

          Author and article information

          Journal
          Hum. Mol. Genet.
          Human molecular genetics
          Oxford University Press (OUP)
          1460-2083
          0964-6906
          Oct 01 2014
          : 23
          : 19
          Affiliations
          [1 ] Service de Génétique, Institut Curie, Paris, France.
          [2 ] Institut Curie, Section Recherche, Orsay, France CNRS UMR3347 INSERM U1021 Université Paris Sud and.
          [3 ] Département d'oncologie chirurgicale, service d'Ophtalmologie, Institut Curie, Paris, France Laboratoire d'Investigation Préclinique, Institut Curie, Paris, France.
          [4 ] Département d'oncologie pédiatrique, adolescents jeunes adultes and.
          [5 ] Département d'oncologie pédiatrique, adolescents jeunes adultes and Université Paris Descartes, Sciences pharmaceutiques et biologiques, Sorbonne Paris Cité, Paris, France.
          [6 ] Département d'oncologie chirurgicale, service d'Ophtalmologie, Institut Curie, Paris, France.
          [7 ] Institut Curie, CNRS UMR 3664, Paris, France.
          [8 ] Service de Génétique, Institut Curie, Paris, France INSERM U830, centre de recherche de l'Institut Curie, Paris, France Université Paris Descartes, Sciences pharmaceutiques et biologiques, Sorbonne Paris Cité, Paris, France.
          [9 ] Institut Curie, Section Recherche, Orsay, France CNRS UMR3347 INSERM U1021 Université Paris Sud and claude.houdayer@curie.fr celio.pouponnot@curie.fr.
          [10 ] Service de Génétique, Institut Curie, Paris, France INSERM U830, centre de recherche de l'Institut Curie, Paris, France Université Paris Descartes, Sciences pharmaceutiques et biologiques, Sorbonne Paris Cité, Paris, France claude.houdayer@curie.fr celio.pouponnot@curie.fr.
          Article
          ddu245
          10.1093/hmg/ddu245
          24858910
          d3b727e1-26c9-421d-b41d-b361d50a522a
          History

          Comments

          Comment on this article